Hasegawa M, Kawashima S, Shikano M, Kojima K, Yanai T, Hassegawa H, Tomita M, Murakami K, Kawamura N, Katsumata H
Department of Nephrology, Fujita Health, University School of Medicine, Toyoake, Japan.
Nephron. 1995;69(4):380-3. doi: 10.1159/000188506.
We studied complexes composed of C1q and beta 2-microglobulin (C1q.beta 2M) or serum amyloid P-component (C1q.SAP) in the sera of 38 patients receiving hemodialysis (HD) and 20 healthy control subjects using an enzyme-linked immunoassay. We also compared complex levels in HD patients with and without symptoms of HD-associated amyloidosis (HA). Serum C1q-beta 2M levels were significantly higher in HD patients without HA than in healthy control subjects and significantly higher in HD patients with HA than in HD patients without HA. Serum C1q.SAP levels were significantly lower in patients with HA than in those without HA. These results suggest that C1q.beta 2M may contribute to HA.
我们使用酶联免疫分析法研究了38例接受血液透析（HD）的患者和20名健康对照者血清中由C1q和β2-微球蛋白组成的复合物（C1q.β2M）或血清淀粉样蛋白P成分（C1q.SAP）。我们还比较了有和没有血液透析相关淀粉样变性（HA）症状的HD患者的复合物水平。无HA的HD患者血清C1q-β2M水平显著高于健康对照者，有HA的HD患者血清C1q-β2M水平显著高于无HA的HD患者。HA患者的血清C1q.SAP水平显著低于无HA的患者。这些结果表明C1q.β2M可能与HA有关。
